66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140
Showing 1 to 10 of 275 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05517980 (ClinicalTrials.gov) | July 1, 2023 | 24/8/2022 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis | An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 in Subjects With IgA Nephropathy (IgAN) and Complement 3 Glomerulopathy (C3G) An Open-label, Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic ... | Glomerulonephritis | Drug: KP104 | Kira Pharmacenticals (US), LLC. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 52 | Phase 2 | NULL |
| 2 | NCT05687890 (ClinicalTrials.gov) | April 2023 | 9/1/2023 | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to Investigate the Safety and Efficacy of SC0062 Capsule in Patients With Chronic Kidney Disease With Albuminuria A Randomized, Double Blind, Placebo Parallel Controlled, 2 Cohorts, Multicenter Phase II Study to In ... | Diabetic Kidney Disease;IgA Nephropathy | Drug: Placebo of SC0062;Drug: SC0062 low dose;Drug: SC0062 medium dose;Drug: SC0062 high dose | Biocity Biopharmaceutics Co., Ltd. | NULL | Not yet recruiting | 18 Years | 70 Years | All | 240 | Phase 2 | NULL |
| 3 | NCT05596708 (ClinicalTrials.gov) | March 1, 2023 | 25/10/2022 | Study of Telitacicept in Patients With Refractory IgA Nephropathy | A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractory IgA Nephropathy A Single-arm, Forward-looking, Exploratory Clinical Study of Telitacicept in Patients With Refractor ... | IgA Nephropathy | Drug: Telitacicept | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 40 | Phase 2/Phase 3 | China |
| 4 | NCT05174221 (ClinicalTrials.gov) | November 9, 2022 | 14/12/2021 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgrou ... | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ... | Kidney Disease | Drug: Mezagitamab | Takeda | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 1 | United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain; ... |
| 5 | EUCTR2020-005855-19-HU (EUCTR) | 03/11/2022 | 08/04/2022 | Evaluating oral BCX9930 in renal diseases | An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy - RENEW An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects ... | complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.0;Classification code 10077827;Term: C3 glomerulopathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Body processes [G] - Immune system processes [G12] complement 3 glomerulopathyimmunoglobulin A nephropathyprimary membranous nephropathy MedDRA version ... | Product Name: BCX9930 Product Code: BCX9930 INN or Proposed INN: BCX9930 Other descriptive name: BCX9930 hydrochloride Product Name: BCX9930 Product Code: BCX9930 INN or Proposed INN: BCX9930 Other descriptive name: BCX9930 hydrochloride Product Name: BCX9930 Product Code: BCX9930 INN or Proposed INN: BCX9930 Other descriptive name: BCX993 ... | BioCryst Pharmaceuticals Inc | NULL | Not Recruiting | Female: yes Male: yes | 42 | Phase 2 | France;Hungary;Spain;Romania;Germany;United Kingdom;Italy | ||
| 6 | NCT05534919 (ClinicalTrials.gov) | September 2022 | 6/9/2022 | Efficacy and Safety in Chinese Patients With Immunoglobulin A Nephropathy (IgAN) Who Have Completed Study Nef-301 Efficacy and Safety in Chinese Patients With Immunoglobulin A Nephropathy (IgAN) Who Have Completed ... | An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Ompleted Study Nef-301 in China An Open-label Extention (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Pati ... | Primary Immunoglobulin A Nephropathy (IgAN) | Drug: Nefecon | Everest Medicines (Singapore) Pte. Ltd. | NULL | Not yet recruiting | 18 Years | N/A | All | 58 | Phase 3 | China |
| 7 | NCT05383547 (ClinicalTrials.gov) | August 2, 2022 | 10/5/2022 | Bortezomib for Treating Glomerular Diseases | Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases | Bortezomib;Glomerulonephritis;MN;MPGN;FSGS;IgA Nephropathy | Drug: Bortezomib | Ruijin Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | N/A | China |
| 8 | ITMCTR2200006488 | 2022-08-01 | 2022-08-15 | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 A clinical study of traditional Chinese medicine combined with western medicine in treatment of prim ... | A clinical study of traditional Chinese medicine combined with western medicine in treatment of primary IgA nephropathy (IgAN) in CKD stage 3 A clinical study of traditional Chinese medicine combined with western medicine in treatment of prim ... | IgA nephropathy | Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 prescription; Valsartan:oral valsartan;group combination of Chinese and Western medicine:Valsartan+Chuanhuang No.1 ... | Shanghai east hospital (East Hospital affiliated to Tongji University) | NULL | Pending | 18 | 75 | Both | Valsartan:42;group combination of Chinese and Western medicine:21; | China | |
| 9 | JPRN-jRCT2011220009 | 17/07/2022 | 15/06/2022 | A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgrou ... | A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ... | Kidney Disease | TAK-079 (Mezagitamab) Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 weeks for 16 weeks in the Main Study. Same dosing regimen will be repeated in LTE Retreatment Period. TAK-079 (Mezagitamab) Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 ... | Nishizawa Atsushi | NULL | Recruiting | >= 18age old | Not applicable | Both | 16 | Phase 1 | Australia;China;Spain;Italy;South Korea;Serbia;Singapore;Taiwan;USA;Belgium;Hungary;UK;Japan |
| 10 | EUCTR2020-001049-38-SK (EUCTR) | 08/07/2022 | 31/05/2022 | Study of efficacy and safety of LNP023 in primary IgA nephropathy patients | A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to eva ... | IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;Sy ... | Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LNP023 HYDROCHLORIDE SALT Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LN ... | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 3 | United States;Taiwan;Slovakia;Thailand;Spain;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Malaysia;Viet Nam;Denmark;Australia;South Africa;Netherlands;China;Korea, Republic of;Czechia;Slovenia;Finland;Turkey;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Belgium;Brazil;Singapore;Norway;Germany;Japan;Sweden United States;Taiwan;Slovakia;Thailand;Spain;Russian Federation;Israel;Chile;Colombia;Italy;India;Fr ... |